Search research articles
Contact Us
Filters
Showing results (531-540 of 542) with videos related to
Page
of 55
Sort By:
Haematologica
|
April 23, 2026
Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results
Michael J Hochman, Amy S Ruppert, Ying Huang, et al.
Cancer Discovery
|
October 30, 2019
The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin, Lars D Engstrom, Lauren Hargis, et al.
Haematologica
|
November 6, 2025
<i>IDH2</i> mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy
Fieke W Hoff, Ying Huang, Rina Li Welkie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 25, 2025
Ziftomenib in Relapsed or Refractory <i>NPM1</i>-Mutated AML
Eunice S Wang, Pau Montesinos, James Foran, et al.
Blood Cancer Discovery
|
September 25, 2020
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating Functions
Giovannino Silvestri, Rossana Trotta, Lorenzo Stramucci, et al.
Journal of Medicinal Chemistry
|
April 7, 2020
Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of Cancer
Jay B Fell, John P Fischer, Brian R Baer, et al.
Nature Medicine
|
October 27, 2020
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
Amy Burd, Ross L Levine, Amy S Ruppert, et al.
Blood Advances
|
October 23, 2023
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML
Sheng F Cai, Ying Huang, Jennie R Lance, et al.
Cancer
|
April 20, 2023
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial
Vu H Duong, Amy S Ruppert, Alice S Mims, et al.
Blood Advances
|
August 7, 2024
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy
Fieke W Hoff, William G Blum, Ying Huang, et al.
Page
of 55
Search research articles
Search
Showing results (531-540 of 542) with videos related to
Sort By:
Page
of 55
Haematologica
|
April 23, 2026
Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results
Michael J Hochman, Amy S Ruppert, Ying Huang, et al.
Cancer Discovery
|
October 30, 2019
The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin, Lars D Engstrom, Lauren Hargis, et al.
Haematologica
|
November 6, 2025
<i>IDH2</i> mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy
Fieke W Hoff, Ying Huang, Rina Li Welkie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 25, 2025
Ziftomenib in Relapsed or Refractory <i>NPM1</i>-Mutated AML
Eunice S Wang, Pau Montesinos, James Foran, et al.
Blood Cancer Discovery
|
September 25, 2020
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating Functions
Giovannino Silvestri, Rossana Trotta, Lorenzo Stramucci, et al.
Journal of Medicinal Chemistry
|
April 7, 2020
Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of Cancer
Jay B Fell, John P Fischer, Brian R Baer, et al.
Nature Medicine
|
October 27, 2020
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
Amy Burd, Ross L Levine, Amy S Ruppert, et al.
Blood Advances
|
October 23, 2023
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML
Sheng F Cai, Ying Huang, Jennie R Lance, et al.
Cancer
|
April 20, 2023
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial
Vu H Duong, Amy S Ruppert, Alice S Mims, et al.
Blood Advances
|
August 7, 2024
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy
Fieke W Hoff, William G Blum, Ying Huang, et al.
Page
of 55